Your browser doesn't support javascript.
loading
The emerging role for CAR T cells in solid tumor oncology.
Klobuch, Sebastian; Seijkens, Tom T P; Haanen, John B A G.
Afiliação
  • Klobuch S; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Seijkens TTP; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Medical Biochemistry, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
  • Haanen JBAG; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
Chin Clin Oncol ; 12(2): 19, 2023 Apr.
Article em En | MEDLINE | ID: mdl-37160670
In recent years, treatment with chimeric antigen receptor (CAR) T-cells has revolutionized the outcomes of patients with relapsed or refractory hematological malignancies with long-term remissions in >30% of patients. Similarly, the introduction of immune checkpoint inhibitor therapy changed the therapeutic landscape for several solid malignancies also leading to impressive long-term remission in patients. However, so far CAR T-cell therapy in solid tumors has shown low response rates and especially a lack of long-term remissions. This review focuses on the latest clinical advances and discusses promising results seen with CAR T-cells exploring new target antigens. We then review relevant challenges limiting long-term responses with CAR T-cell therapy in solid tumors like CAR T-cell persistence and target antigen expression. In addition, there is an increasing understanding on T-cell function and dysfunction within the immunosuppressive tumor microenvironment. This comprises of inhibitory cytokines and checkpoint molecules limiting the killing capacity of CAR T-cells. Finally, we will discuss how this deeper knowledge can be used to develop CAR T-cell therapies overcoming these inhibitory factors and results in CAR T-cell products with higher efficacy and safety. These technological developments will hopefully lead to enhanced clinical activity and improved solid tumor patient outcomes in the near future.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Limite: Humans Idioma: En Revista: Chin Clin Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda País de publicação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Limite: Humans Idioma: En Revista: Chin Clin Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda País de publicação: China